ACADIA Pharmaceuticals Inc.

NAS: ACAD

GO
/marketstate/country/us

After Hours

 --Real time quotes

Jan 25, 2022, 4:07 p.m.

/zigman2/quotes/205236646/composite

$

21.59

Change

-0.34 -1.55%

Volume

Volume 85,535

Real time quotes

/zigman2/quotes/205236646/composite

Today's close

$ 22.45

$ 21.93

Change

-0.52 -2.32%

Day low

Day high

$21.30

$22.17

Open

52 week low

52 week high

$15.68

$54.50

Open

Insider Actions for ACADIA Pharmaceuticals Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/06/2022 Stephen R. Davis
CEO; Director
3,718   Disposition at $23.05 per share. 85,699
01/06/2022 Srdjan R. Stankovic
President
1,937   Disposition at $23.05 per share. 44,647
01/06/2022 Austin D. Kim
EVP & General Counsel
574   Disposition at $23.05 per share. 13,230
01/06/2022 Brendan P. Teehan
EVP, COO, Head of Commercial
538   Disposition at $23.05 per share. 12,400
01/06/2022 Stephen R. Davis
CEO; Director
9,527   Derivative/Non-derivative trans. at $0 per share. 0
01/06/2022 Srdjan R. Stankovic
President
5,444   Derivative/Non-derivative trans. at $0 per share. 0
01/06/2022 Austin D. Kim
EVP & General Counsel
1,633   Derivative/Non-derivative trans. at $0 per share. 0
01/06/2022 Brendan P. Teehan
EVP, COO, Head of Commercial
1,286   Derivative/Non-derivative trans. at $0 per share. 0
11/22/2021 Srdjan R. Stankovic
President
2,803   Disposition at $19.01 per share. 53,285
11/19/2021 Srdjan R. Stankovic
President
6,250   Derivative/Non-derivative trans. at $0 per share. 0
10/18/2021 Stephen R. Davis
CEO; Director
2,963   Disposition at $17.41 per share. 51,585
10/18/2021 Srdjan R. Stankovic
President
1,338   Disposition at $17.41 per share. 23,294
10/15/2021 Stephen R. Davis
CEO; Director
5,938   Derivative/Non-derivative trans. at $0 per share. 0
10/15/2021 Srdjan R. Stankovic
President
2,969   Derivative/Non-derivative trans. at $0 per share. 0
09/29/2021 Elizabeth A Garofalo
Director
1,918   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 Baker Bros. Advisors LP
Director
12,782   Award at $0 per share. 0
06/22/2021 Baker Bros. Advisors LP
Director
12,782   Award at $0 per share. 0
04/30/2021 Stephen R. Davis
CEO; Director
7,850   Disposition at $20.33 per share. 159,590
04/30/2021 Srdjan R. Stankovic
President
4,230   Disposition at $20.33 per share. 85,995
04/30/2021 Austin D. Kim
EVP & General Counsel
1,054   Disposition at $20.33 per share. 21,427
04/30/2021 Elena H. Ridloff
EVP and CFO
1,032   Disposition at $20.33 per share. 20,980
04/29/2021 Stephen R. Davis
CEO; Director
15,625   Derivative/Non-derivative trans. at $0 per share. 0
04/29/2021 Srdjan R. Stankovic
President
9,615   Derivative/Non-derivative trans. at $0 per share. 0
04/29/2021 Austin D. Kim
EVP & General Counsel
3,005   Derivative/Non-derivative trans. at $0 per share. 0
04/29/2021 Elena H. Ridloff
EVP and CFO
3,245   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Stephen R. Davis
CEO; Director
14,195   Disposition at $50.61 per share. 718,408
02/04/2021 Srdjan R. Stankovic
President
8,429   Disposition at $50.61 per share. 426,591
02/04/2021 Austin D. Kim
EVP & General Counsel
2,107   Disposition at $50.61 per share. 106,635
02/04/2021 Elena H. Ridloff
EVP and CFO
2,051   Disposition at $50.61 per share. 103,801
02/04/2021 Stephen R. Davis
CEO; Director
31,250   Award at $0 per share. 0
02/04/2021 Srdjan R. Stankovic
President
19,231   Award at $0 per share. 0
02/04/2021 Austin D. Kim
EVP & General Counsel
6,009   Award at $0 per share. 0
02/04/2021 Elena H. Ridloff
EVP and CFO
6,490   Award at $0 per share. 0

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
5 Purchases
5 Sales
24,140
9,570
Last 6 months
8 Purchases
7 Sales
34,965
13,871
Last 12 months
18 Purchases
15 Sales
154,999
54,819

Officers and Executives

Mr. Stephen R. Davis
Chief Executive Officer & Director
Dr. Srdjan R. Stankovic
President
Mr. Brendan P. Teehan
Chief Operating Officer, EVP & Head-Commercial
Mr. Mark Schneyer
Chief Financial & Business Officer
Dr. Ponni Subbiah
Chief Medical Officer & Senior Vice President
Dr. Spyros Papapetropoulos
Senior Vice President & Head-Clinical Development
Mr. Bob Mischler
Senior VP-Strategy & Technology Operations
Dr. Katherine M. Bishop
Senior Vice President & Head-Rare Disease
Ms. Julie Fisher
Senior VP-Marketing & Commercial Strategy
Mr. James K. Kihara
Vice President & Controller
Mr. Mark Johnson
Vice President-Investor Relations
Mr. Austin D. Kim
Secretary, Executive VP & General Counsel
Mr. Daryl DeKarske
Senior VP & Head-Global Regulatory Affairs
Dr. Stephen R. Biggar
Chairman
Dr. Elizabeth A Garofalo
Independent Director
Ms. Laura A. Brege
Independent Director
Mr. Daniel B. Soland
Independent Director
Dr. Edmund P. Harrigan
Independent Director
Mr. Julian Charles Baker
Independent Director
Mr. James M. Daly
Independent Director
Link to MarketWatch's Slice.